Published: October 2010
Subcutaneous Metastatic Adenocarcinoma: An Unusual Presentation of Colon Cancer – Case Report and Literature ReviewLlaguna O.H.a · Desai P.b · Fender A.B.c · Zedek D.C.d · Meyers M.O.a · O’Neil B.H.b · Diaz L.A.c · Calvo B.F.a
aDivision of Surgical Oncology and Endocrine Surgery, bDivision of Hematology and Oncology, cDepartment of Dermatology, and dDepartment of Pathology and Laboratory Medicine, University of North Carolina School of Medicine, Chapel Hill, N.C., USA
Omar H. Llaguna, MD
Division of Surgical Oncology and Endocrine Surgery University of North Carolina, 170 Manning Drive, 1150 Physicians Office Building
Chapel Hill, NC 27599 (USA)
Tel. +1 919 966 5221, Fax +1 919 966 8806, E-Mail email@example.com
Do you have an account?
Subcutaneous metastasis from a visceral malignancy is rare with an incidence of 5.3%. Skin involvement as the presenting sign of a silent internal malignancy is an even rarer event occurring in approximately 0.8%. We report a case of a patient who presented to her dermatologist complaining of rapidly developing subcutaneous nodules which subsequently proved to be metastatic colon cancer, and we provide a review of the literature.
© 2011 S. Karger AG, Basel
Article / Publication Details
Open Access License / Drug Dosage / DisclaimerOpen Access License: This is an Open Access article licensed under the terms of the Creative Commons Attribution-NonCommercial 3.0 Unported license (CC BY-NC) (www.karger.com/OA-license), applicable to the online version of the article only. Distribution permitted for non-commercial purposes only.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.